Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin

Liu,Liancheng; Bai,Zhigang; Ma,Xuemei; Wang,Tingting; Yang,Yao; Zhang,Zhongtao

doi:10.3892/etm.2016.2994

Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin

Authors:
- Liancheng Liu
- Zhigang Bai
- Xuemei Ma
- Tingting Wang
- Yao Yang
- Zhongtao Zhang
View Affiliations

Affiliations: Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: January 13, 2016 https://doi.org/10.3892/etm.2016.2994
Pages: 846-852
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the role of taxol resistance gene 1 (Txr1) in the development of oxaliplatin (L-OHP) resistance in gastric cancer (GC). Using SGC-7901 cells as a model, Txr1 was exogenously expressed or knocked down using small interfering RNA. Quantitative polymerase chain reaction (qPCR) and western blotting were performed to establish whether the Txr1 gene is involved in chemoresistance, and cell proliferation was assessed using an MTS assay. To this end, the mRNA and protein levels of Txr1, thrombospondin‑1 and excision repair cross‑complementing 1 protein were measured using qPCR and western blotting, respectively. Txr1‑knockdown significantly increased the sensitivity of the SGC‑7901 cells to L‑OHP, whereas Txr1 overexpression promoted the resistance of the SGC‑7901 cells to L‑OHP. Exogenous Txr1 expression in the SGC‑7901 cells induced L‑OHP resistance, and the siRNA knockdown of Txr1 sensitized the human GC cells to L‑OHP. Txr1 is, therefore, likely to play a role in L‑OHP resistance, acting via TSP1, and should be investigated as a potential therapeutic target in the treatment of GC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Foo M and Leong T: Adjuvant therapy for gastric cancer: Current and future directions. World J Gastroenterol. 20:13718–13727. 2014. View Article : Google Scholar : PubMed/NCBI
3	Park SC and Chun HJ: Chemotherapy for advanced gastric cancer: Review and update of current practices. Gut Liver. 7:385–393. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zhao Q, Zhang H, Li Y, Liu J, Hu X and Fan L: Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res. 29:1182010. View Article : Google Scholar : PubMed/NCBI
5	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
6	Wang J, Zhou XQ, Li JY, Cheng JF, Zeng XN, Li X and Liu P: Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer. Chin J Cancer Res. 26:323–330. 2014.PubMed/NCBI
7	Yao A, Wang Y, Peng X, Ye R, Wang Q, Qi Y and Zhou F: Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: A meta-analysis. J Cancer Res Clin Oncol. 140:2107–2117. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lih CJ, Wei W and Cohen SN: Txr1: A transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev. 20:2082–2095. 2006. View Article : Google Scholar : PubMed/NCBI
9	Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki1 E, Georgoulias V and Souglakos J: Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res. 15:3827–3833. 2009. View Article : Google Scholar : PubMed/NCBI
10	Bai Z, Zhang Z, Qu X, Han W and Ma X: Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1. Oncol Lett. 3:135–140. 2012.PubMed/NCBI
11	Bai ZG, Qu X, Han W, Ma XM, Zhao XM and Zhang ZT: Expression of taxol resistance gene 1 correlates with gastric cancer patient clinical outcome and induces taxol resistance. Mol Med Rep. 3:1071–1078. 2010.PubMed/NCBI
12	Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D: European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO): ESMO; ESSO; ESTRO: Gastric cancer: cancer: Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. J Eur J Surg Oncol. 40:584–591. 2014. View Article : Google Scholar : PubMed/NCBI
13	GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
14	Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D: European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); and European Society of Radiotherapy and Oncology (ESTRO): Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi57–vi63. 2013. View Article : Google Scholar : PubMed/NCBI
15	Alian OM, Azmi AS and Mohammad RM: Network insights on oxaliplatin anti-cancer mechanisms. Clin Transl Med. 1:262012. View Article : Google Scholar : PubMed/NCBI
16	Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, et al: CLASSIC trial investigators: Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 15:1389–1396. 2014. View Article : Google Scholar : PubMed/NCBI
17	Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, Cavaliere C, Nasti G, Facchini G and Berretta M: Current strategies to minimize toxicity of oxaliplatin: Selection of pharmacogenomic panel tests. Anticancer Drugs. 24:1069–1078. 2013. View Article : Google Scholar : PubMed/NCBI
18	Bi J, Bai Z, Ma X, Song J, Guo Y, Zhao J, Yi X, Han S and Zhang Z: Txr1: An important factor in oxaliplatin resistance in gastric cancer. Med Oncol. 31:8072014. View Article : Google Scholar : PubMed/NCBI
19	Sid B, Sartelet H, Bellon G, El Btaouri H, Rath G, Delorme N, Haye B and Martiny L: Thrombospondin. 1 A multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol. 49:245–258. 2004. View Article : Google Scholar : PubMed/NCBI
20	van Amerongen R and Berns A: TXR1-mediated thrombospondin repression: A novel mechanism of resistance to taxanes? Genes Dev. 20:1975–1981. 2006. View Article : Google Scholar : PubMed/NCBI
21	Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V and Souglakos J: Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer. 104:316–323. 2011. View Article : Google Scholar : PubMed/NCBI
22	Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z, Yang Z and Kuang G: Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol. 2010:7214852010. View Article : Google Scholar : PubMed/NCBI
23	Reardon JT, Vaisman A, Chaney SG and Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 59:3968–3971. 1999.PubMed/NCBI
24	Deng Q, Yang H, Lin Y, Qiu Y, Gu X, He P, Zhao M, Wang H, Xu Y, Lin Y, et al: Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China. Int J Clin Exp Pathol. 7:8312–8321. 2014.PubMed/NCBI
25	Lee KB, Parker RJ, Bohr V, Cornelison T and Reed E: Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis. 14:2177–2180. 1993. View Article : Google Scholar : PubMed/NCBI
26	Melton DW, Ketchen AM, Núñez F, Bonatti-Abbondandolo S, Abbondandolo A, Squires S and Johnson RT: Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci. 111:395–404. 1998.PubMed/NCBI
27	Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH and You HJ: Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res. 64:4849–4857. 2004. View Article : Google Scholar : PubMed/NCBI
28	Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 16:309–316. 1998.PubMed/NCBI
29	Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 24:331–344. 1998. View Article : Google Scholar : PubMed/NCBI
30	Wood RD, Mitchell M, Sgouros J and Lindahl T: Human DNA repair genes. Science. 291:1284–1289. 2001. View Article : Google Scholar : PubMed/NCBI
31	Reed E, Yu JJ, Davies A, Gannon J and Armentrout SL: Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res. 9:5299–5305. 2003.PubMed/NCBI
32	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI